Eckert & Ziegler Strahlen und Medizintechnik AG
XETRA:EUZ
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/EBIT
Enterprise Value to EBIT (EV/EBIT) ratio compares a company`s total enterprise value to its earnings before interest and taxes. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Enterprise Value to EBIT (EV/EBIT) ratio compares a company`s total enterprise value to its earnings before interest and taxes. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Valuation Scenarios
If EV/EBIT returns to its 3-Year Average (15.1), the stock would be worth €19.77 (36% upside from current price).
| Scenario | EV/EBIT Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 11.1 | €14.53 |
0%
|
| 3-Year Average | 15.1 | €19.77 |
+36%
|
| 5-Year Average | 16.2 | €21.3 |
+47%
|
| Industry Average | 16.2 | €21.26 |
+46%
|
| Country Average | 15.5 | €20.41 |
+40%
|
Forward EV/EBIT
Today’s price vs future ebit
| Today's Enterprise Value | EBIT | Forward EV/EBIT | ||
|---|---|---|---|---|
|
€830.1m
|
/ |
Jan 2026
€73.7m
|
= |
|
|
€830.1m
|
/ |
Dec 2026
€79.6m
|
= |
|
|
€830.1m
|
/ |
Dec 2027
€89.6m
|
= |
|
|
€830.1m
|
/ |
Dec 2028
€94.1m
|
= |
|
Forward EV/EBIT shows whether today’s EV/EBIT still looks high or low once future ebit are taken into account.
Peer Comparison
| Market Cap | EV/EBIT | P/E | ||||
|---|---|---|---|---|---|---|
| DE |
|
Eckert & Ziegler Strahlen und Medizintechnik AG
XETRA:EUZ
|
909.2m EUR | 11.1 | 18.4 | |
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
171.2B USD | 55.9 | 60 | |
| US |
|
Abbott Laboratories
NYSE:ABT
|
158.3B USD | 18.8 | 25.2 | |
| US |
|
Stryker Corp
NYSE:SYK
|
125.3B USD | 23.9 | 38.6 | |
| IE |
|
Medtronic PLC
NYSE:MDT
|
106.9B USD | 18.8 | 23.2 | |
| US |
|
Boston Scientific Corp
NYSE:BSX
|
92B USD | 25.3 | 31.8 | |
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
40B EUR | 15.1 | 18.9 | |
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
48.9B USD | 27.2 | 45.5 | |
| US |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
45.1B USD | 33.3 | 42.6 | |
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
43.3B USD | 16.6 | 24.7 | |
| US |
|
Resmed Inc
NYSE:RMD
|
32B USD | 16.8 | 21.6 |
Market Distribution
| Min | 0.1 |
| 30th Percentile | 10.6 |
| Median | 15.5 |
| 70th Percentile | 23.1 |
| Max | 672.9 |
Other Multiples
Eckert & Ziegler Strahlen und Medizintechnik AG
Glance View
Eckert & Ziegler Strahlen- und Medizintechnik AG engages in the provision of isotope technology for medical, scientific, and industrial use. The company is headquartered in Berlin, Berlin and currently employs 866 full-time employees. The company went IPO on 2008-02-25. The firm operates through three segments: Radiation Therapy, Isotope Products and Radiopharma. The Radiation Therapy segment operates through Eckert & Ziegler BEBIG and produces and distributes medical products for the treatment of cancer using brachytherapy. The Isotope Products segment provides sealed and unsealed radiation sources for medical imaging, industrial gauging, measurement and analysis, reference, calibration and environmental monitoring sources and solutions, as well as bulk radioisotopes for pharmaceutical, therapeutic and industrial product manufacturers. The Radiopharma segment specializes in molecular imaging and nuclear medicine, and supplies various radiopharmaceuticals, radiochemicals and related equipment.
